☆ 4.6 Article

Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: A retrospective cohort study of clinical effectiveness

FRONTIERS IN PSYCHIATRY (2022)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls

Martina Calusic et al.

Summary: Fluvoxamine, as an early treatment option, has shown promise in preventing COVID-19 progression in three trials. This study evaluated the safety and efficacy of fluvoxamine in COVID-19 patients when administered later in the disease course. The results suggest that fluvoxamine treatment in addition to standard therapy may have a positive impact on patient survival, but further studies are needed to confirm these findings.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Mechanisms of action of fluvoxamine for COVID-19: a historical review

Yaeko Hashimoto et al.

Summary: The ongoing COVID-19 pandemic has sparked interest in drug repurposing, particularly in the use of antidepressants. Clinical data suggest that early-stage COVID-19 patients who take antidepressants may have a lower risk of intubation or death. Fluvoxamine, among antidepressants, is the most attractive drug for mild to moderate COVID-19 cases. Additionally, there may be a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders in offspring, such as autism spectrum disorder and schizophrenia.

MOLECULAR PSYCHIATRY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

Gilmar Reis et al.

Summary: Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to a tertiary hospital. The trial showed a higher probability of superiority (99.8%) surpassing the prespecified threshold of 97.6%.

LANCET GLOBAL HEALTH (2022)

Add to Collection

Article Medicine, General & Internal

Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis

Steven H. Rauchman et al.

Summary: Short-term use of SSRI antidepressants can reduce the severity of symptoms in COVID-positive patients. This study highlights the usefulness of large clinical databases in identifying commonly used drugs that may be helpful in treating COVID-19.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Letter Clinical Neurology

Old drug fluvoxamine, new hope for COVID-19

Yaeko Hashimoto et al.

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Noam Barda et al.

Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study

Nicolas Hoertel et al.

Summary: This study suggests that the use of antidepressants in patients hospitalized for COVID-19 may be associated with a lower risk of death or intubation. Antidepressants such as fluoxetine, paroxetine, escitalopram, venlafaxine, and mirtazapine showed significant associations with reduced risk. Further research in the form of double-blind controlled randomized clinical trials is recommended.

MOLECULAR PSYCHIATRY (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

David Seftel et al.

Summary: In this study, 65 individuals opted to receive fluvoxamine for COVID-19 treatment, with a 0% hospitalization rate and 0% residual symptoms. In comparison, 48 individuals who chose observation alone had a hospitalization rate of 12.5% and residual symptoms in 60% of cases. This suggests that fluvoxamine may help alleviate the severity and duration of COVID-19.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Psychiatry

Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish inpatients

Crisanto Diez-Quevedo et al.

Summary: The study found that mental disorders are common in COVID-19 patients and that receiving psychopharmacological treatments may affect mortality rate. Therefore, timely detection and treatment of mental disorders are crucial for the prognosis and functional recovery of the disease.

ACTA PSYCHIATRICA SCANDINAVICA (2021)

Add to Collection

Article Pharmacology & Pharmacy

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro

Sebastian Schloer et al.

Summary: The combination of itraconazole-remdesivir and fluoxetine-remdesivir effectively inhibits the production of infectious SARS-CoV-2 particles with synergistic effects, showing promising therapeutic options for controlling COVID-19.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants

Tomiko Oskotsky et al.

Summary: This study investigated the association of SSRIs with outcomes in patients with COVID-19 using electronic health records. The results suggest that SSRIs, especially fluoxetine, may be associated with reduced mortality in COVID-19 patients. Further research and clinical trials are needed to confirm these findings.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Multidisciplinary Sciences

The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue

Melissa Zimniak et al.

Summary: Research has found that Fluoxetine can effectively inhibit SARS-CoV-2 infection and show activity in human lung tissue. Both stereoisomers of Fluoxetine exhibit similar activity against the virus, with the R-form possibly being specifically used for SARS-CoV-2 treatment.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Clinical Neurology

FLUOXETINE USE IS ASSOCIATED WITH IMPROVED SURVIVAL OF PATIENTS WITH COVID-19 PNEUMONIA: A RETROSPECTIVE CASE-CONTROL STUDY

Zsofia Klara Nemeth et al.

Summary: This study investigated the association between fluoxetine use and survival in hospitalized COVID-19 pneumonia patients, finding that fluoxetine was associated with a significant decrease in mortality.

IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE (2021)

Add to Collection

Review Psychiatry

Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis

Benedetta Vai et al.

Summary: This systematic review and meta-analysis found that pre-existing mental disorders, specifically psychotic and mood disorders, and exposure to antipsychotics and anxiolytics were associated with an increased risk of COVID-19 mortality. The study highlighted the need for targeted approaches to manage and prevent COVID-19 in at-risk patient groups identified in this study. Further research is needed to determine the underlying mechanisms of these associations.

LANCET PSYCHIATRY (2021)

Add to Collection

Article Multidisciplinary Sciences

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

David E. Gordon et al.

NATURE (2020)

Add to Collection

Article Neurosciences

Further evidence of low adherence to stimulant treatment in adult ADHD: an electronic medical record study examining timely renewal of a stimulant prescription

Joseph Biederman et al.

PSYCHOPHARMACOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

David E. Gordon et al.

SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial

Eric J. Lenze et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Cell Biology

Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells

Alexander Carpinteiro et al.

CELL REPORTS MEDICINE (2020)

Add to Collection

Article Immunology

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

Sebastian Schloer et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Article Medical Informatics

Screening pregnant women for suicidal behavior in electronic medical records: diagnostic codes vs. clinical notes processed by natural language processing

Qiu-Yue Zhong et al.

BMC MEDICAL INFORMATICS AND DECISION MAKING (2018)

Add to Collection

Article Clinical Neurology

Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome

Yulia Orlova et al.

JAMA NEUROLOGY (2018)

Add to Collection

Article Public, Environmental & Occupational Health

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available

Miguel A. Hernan et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)

Add to Collection

Editorial Material Medicine, General & Internal

Confounding by Indication in Clinical Research

Demetrios N. Kyriacou et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Add to Collection

Article Computer Science, Information Systems

Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2)

Shawn N. Murphy et al.

JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.